首页|Identifying genetic targets in clinical subtypes of Parkinson's disease for optimizing pharmacological treatment strategies

Identifying genetic targets in clinical subtypes of Parkinson's disease for optimizing pharmacological treatment strategies

扫码查看
原文链接
  • 万方数据
The heterogeneity of Parkinson's disease(PD)has been recognized in clinical,with patients categorized into distinct subsets based on motor phenotype,such as tremor-dominant PD(TD),postural instability and gait difficulty-dominant PD(PIGD)and mixed PD(Mix).Despite this categorization,the underlying mechanisms of this heterogeneity remain poorly understood,and there is no personalized effective treatment for each PD subtype.To address this,a rat model for PD subtypes was established by unilateral stereotaxic injection of 6-OHDA,followed by cluster analysis of behavioral data.The serum neurofilament light chain(NfL)and uric acid(UA)levels as well as alterations in brain autonomic activity in rats were consistent with clinical patients,and metabolomics results showed that more than 70％of the metabolites in the serum of different subtypes of PD rats and clinical patients appeared to be consistently altered.Further transcriptomic analysis by RNA-seq has elucidated that the development of PD subtypes is associated with altered gene expression in neurotransmitter,neuronal damage in the central or peripheral nervous system,and lipid metabolism.In addition,based on the subtype-specific differentially expressed genes,25 potential drug candidates were identified.Notably,the Alox15 inhibitor baicalein showed a greater efficacy on Mix rats,highlighting the possibility of selecting targeted treatments for well-defined individuals.

Dewen Kong、Cao Li、LingYan Ma、Lida Du、Nan Jiang、Xiaoyue Zhao、Sen Zhang、Zhigang Zhao、Lianhua Fang、Guanhua Du

展开 >

State Key Laboratory of Bioactive Substances and Functions of Natural Medicines,Beijing Key Laboratory of Drug Target Identification and Drug Screening,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China

Department of Pharmacy,Beijing Tiantan Hospital,Capital Medical University,Beijing,China

Center for Movement Disorders,Department of Neurology,Beijing Tiantan Hospital,Capital Medical University,Beijing,China

China National Clinical Research Center for Neurological Diseases,Beijing,China

Institute of Molecular Medicine & Innovative Pharmaceutics,Qingdao University,Qingdao,China

School of Pharmacy,Henan University,Kaifeng,China

Medical Science Research Center,Peking Union Medical College Hospital,Chinese Academy of Medical Science and Peking Union Medical College,Beijing,China

展开 >

2024

10.1038/s41392-024-02020-x

信号转导与靶向治疗(英文)

信号转导与靶向治疗(英文)

CSTPCD
ISSN：
年,卷(期)：2024.9(12)